The Development and Prospects for Antivirals for COVID-19
Recording now available
Presented by Dr. D. Lorne Tyrrell
D. Lorne Tyrrell is a Distinguished University Professor at the University of Alberta.
He is the Founding Director of the Li Ka Shing Institute of Virology. He has focused
his research since 1986 on viral hepatitis. His work on the development of antiviral
therapy was supported by CIHR and Glaxo Canada. It resulted in the licensing of the
first oral antiviral agent to treat chronic hepatitis B infection – lamivudine – in 1998.
Today, lamivudine is licensed in over 200 countries worldwide for the treatment of